Article Text

Download PDFPDF
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  1. Katherine M. Bell-McGuinn, MD, PhD*,
  2. Jason A. Konner, MD*,
  3. William P. Tew, MD*,
  4. Martee L. Hensley, MD*,
  5. Alexia Iasonos, PhD,
  6. Eric Charpentier, PhD,
  7. Svetlana Mironov, MD§,
  8. Paul Sabbatini, MD* and
  9. Carol Aghajanian, MD*
  1. *Departments of Medicine and
  2. Departments of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY;
  3. Departments of Sanofi Statistics Department, Cambridge MA; and
  4. §Departments of Department of Radiology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
  1. Address correspondence and reprint requests to Katherine M. Bell-McGuinn, MD, PhD, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065. E-mail: bell-mck@mskcc.org.

Abstract

Objective The aim of the study was to evaluate the activity and tolerability of iniparib monotherapy in women with BRCA1 or BRCA2-associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Methods and Materials Eligible patients had advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, germline BRCA1 or BRCA2 mutation, measurable disease, and at least 1 previous treatment regimen of platinum/taxane chemotherapy. Patients received iniparib 8 mg/kg intravenously on days 1 and 4 weekly, with imaging every 8 weeks. Treatment continued until disease progression or adverse events (AEs) prohibited further therapy. Common Terminology Criteria for AEs v3.0 was used to grade AEs. The primary endpoint was tumor response. The study was conducted with a Simon 2-stage design with 12 and 23 patients planned in the first and second stage, respectively. The study was designed to distinguish between 10% and 30% responding with types 1 and 2 error of 0.10.

Results Twelve patients were treated on study, with median exposure to iniparib of 7.5 weeks. The median number of previous chemotherapeutic regimens was 7. Treatment-related AEs (≥10%) included asthenia (83.3%), constipation (25%), diarrhea (25%), nausea (25%), abdominal pain (16.7%), and decreased hemoglobin (16.7%). All treatment-related AEs were grades 1 or 2 with the following 2 exceptions: 1 grade 3 diarrhea and 1 grade 3 hypertension. One patient had stable disease lasting 2 cycles; the remaining 11 patients had progressive disease. The study did not proceed to second stage enrollment.

Conclusions Iniparib did not show significant activity in this heavily pretreated ovarian cancer population, all of whom had BRCA1 or BRCA2 mutations.

  • Iniparib
  • Ovarian carcinoma
  • Fallopian tube carcinoma
  • Primary peritoneal carcinoma
  • BRCA

Statistics from Altmetric.com

Footnotes

  • This study is funded by Sanofi (NCT00677079).

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.